26.08
FDA grants expedited approval to first pill targeting mutated protein in pancreatic cancer
The US Food and Drug Administration has approved daraxonrasib, a first-of-a-kind oral drug that blocks a mutated protein driving tumor growth in more than 90% of pancreatic cancer cases, of…